[Skip to content]
Susan Calne outlines how drug therapy can be responsible for addictive behaviour in PD patients
Arja Hoglund describes the work she does at the Karolinska hospital in Stockholm
A guide for people with Parkinson’s, their families and healthcare professionals has been developed in partnership between the EPDA, H Lundbeck A/S and Teva Pharmaceutical Industries Ltd.
On December 15 and 16, 2005, the European Federation of Neurological Associations (EFNA) held an important European conference, conducted as an open and interactive forum where – for the first time – the focus was on what patients thought about stem cell research and therapy.
Peter LeWitt describes how PD is managed in the United States.
Lynn Taurah, Alison Forbes, and K Ray Chaudhuri describe the aims and achievements of the PDLIFE study
Jelka Jansa discusses how occupational therapy can help patients with PD improve their daily quality of life
Jane Mills discusses how the British government’s plans to instigate a patient-led NHS will change the roles of healthcare professionals
A Swedish study has shown that two weeks of local administration of sNN0031 – a compound under development for PD – normalised movement and restored dopamine balance in a rat model.
Scientists working in Britain and Belgium have identified 570 genes that behave abnormally during the development of PD.
A multi-centre study of deep brain stimulation (DBS) of either the subthalamic nucleus (STN) or the globus pallidus (GPi) has shown that the treatment continues to provide significant benefit even after four years of treatment.
The ADAGIO study (Attenuation of Disease progression with AGILECT®/ AZILECT® Once-daily), the largest clinical study to investigate disease modification in PD, has now begun enrolling in Europe and North America.
A US study in animals has shown that genetically modified nerve ‘progenitor’ cells can be used as minipumps to deliver nerve growth factor to the brain. Using rats with parkinsonian symptoms, the researchers investigated the effect of human neural progenitor cells engineered to produce glial cell line-derived neurotrophic factor (GDNF).